MedTrace Logo

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

NCT01111955 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

BMS-823778

Capsules, Oral, 2 mg, once daily, 28 days

DRUG

BMS-823778

Capsules, Oral, 10 mg, once daily, 28 days

DRUG

BMS-823778

Capsules, Oral, 20 mg, once daily, 28 days

DRUG

Placebo

Capsules, Oral, 0 mg, once daily, 28 days

DRUG

Metformin

Capsules, Oral, ≥ 1500 mg, once daily, 28 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01111955 on ClinicalTrials.gov